Skip to main content
Bone DensityNutrition and dietSupplementsWeight lossBehavioralDietary supplement

What this study is

The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.

What's being tested

  • Peanut Snack Experimental

    Intervention · DIETARY SUPPLEMENT

    Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss

  • Nut-free Snack

    Intervention · DIETARY SUPPLEMENT

    Subjects will receive a daily no-nut snack and nutrition education-behavior modification instructions for weight loss

Study details

Official title
Metabolic Health, Bones and Nuts Sources of Fatty Acids During Weight Loss in Adults
Sponsor
Rutgers, The State University of New Jersey
Conditions
Weight Loss · Bone Density · Obesity and Overweight
Enrolling
44 people
Starts
2025-10-30
Est. completion
2027-12-31
Design
Quadruple-blind, randomized, parallel groups
Record
View on ClinicalTrials.gov ↗